Ocugen Stock (NASDAQ:OCGN)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$0.90

52W Range

$0.36 - $2.10

50D Avg

$0.98

200D Avg

$1.29

Market Cap

$264.34M

Avg Vol (3M)

$3.65M

Beta

3.77

Div Yield

-

OCGN Company Profile


Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410, gene therapy candidate for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. Ocugen, Inc. has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

65

IPO Date

Dec 03, 2014

Website

OCGN Performance


OCGN Financial Summary


Dec 23Dec 22Dec 21
Revenue---
Operating Income---
Net Income---
EBITDA---
Basic EPS---
Diluted EPS---

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q3 24Nov 08, 24 | 10:18 AM
Q2 24Aug 08, 24 | 12:17 PM
Q1 24May 14, 24 | 12:00 AM

Peer Comparison


TickerCompany
CWBRCohBar, Inc.
AVROAVROBIO, Inc.
VXRTVaxart, Inc.
OCEAOcean Biomedical, Inc.
HEPAHepion Pharmaceuticals, Inc.
NVAXNovavax, Inc.
ZURAZura Bio Limited
ELEVElevation Oncology, Inc.
ENVBEnveric Biosciences, Inc.